Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fusen Pharmaceutical has received approval from China’s National Medical Products Administration to market its Acetylcysteine Effervescent Tablet for treating chronic respiratory diseases like COPD. This approval positions Fusen to capitalize on a substantial market, with the tablet offering benefits such as reduced gastrointestinal irritation and improved patient compliance. The product enriches Fusen’s lineup in respiratory care, aligning with medical guidelines and promising safety and efficacy comparable to existing treatments.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.